D.E. Shaw ups Endo Pharmaceuticals stake to 7.3%

By Laura Lutz

Des Moines, Oct. 12 - Affiliates of D.E. Shaw Composite International Fund increased their ownership of Endo Pharmaceuticals Holdings Inc. to 7.3% from 5.6%, according to an schedule 13D/A filing with the Securities and Exchange Commission.

The investors bought a total of 2,278,201 shares between Aug. 14 and Oct. 11, at prices ranging from $26.97 to $35.00 per share. The investors now own 9,732,018 shares of Endo.

Endo is a pharmaceutical company based in Chadds Ford, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.